$32.00
Manufacturer: Finland
symptoms associated with estrogen deficiency in natural or artificial menopause; for the prevention of postmenopausal osteoporosis with a high risk of fracture, when other medications for the prevention of osteoporosis are contraindicated or unsuitable.
Description
Divigel Composition
active substance: estradiol;
1 sachet contains estradiol hemihydrate equivalent to 0.5 mg or 1 mg of estradiol;
Divigel excipients: carbomer 974R, triethanolamine, propylene glycol, ethanol 96%, purified water.
Divigel Dosage form.
Gel.
Basic physical and chemical properties:
homogeneous opalescent gel.
Pharmacotherapeutic group.
Simple preparations of natural and semi-synthetic estrogens. Estradiol. ATX code G03C A03.
Pharmacological properties
Pharmacodynamics.
Estradiol valerate, which is a synthetic 17b-estradiol, is chemically and biologically identical to endogenous human estradiol. It compensates for the decreased levels of estrogen in menopausal women, thus alleviating the symptoms of menopause. Estrogens prevent bone loss that occurs during menopause or after oophorectomy.
Transdermal administration of estradiol in conjunction with medroxyprogesterone acetate helps to reduce total cholesterol levels without changing high-density lipoprotein cholesterol. The effectiveness of Divigel for correcting a decrease in bone density in the postmenopausal period is the same as with the use of oral estrogen drugs.
Indications
Symptoms associated with estrogen deficiency in natural or artificial menopause.
For the prevention of postmenopausal osteoporosis with a high risk of fracture, when other drugs for the prevention of osteoporosis are contraindicated or unsuitable.
Contraindications
Breast cancer (diagnosed, suspected, or history).
Diagnosed or suspected estrogen-dependent cancers (eg, endometrial cancer).
Vaginal bleeding of unexplained etiology.
Untreated endometrial hyperplasia.
Thromboembolic diseases of the veins, including a history of (deep vein thrombosis (DVT), pulmonary embolism).
A diagnosed increased blood clotting (eg, protein C, protein S, or antithrombin deficiency).
Acute thromboembolism of the arteries, including a history (eg, angina pectoris, myocardial infarction).
Acute liver disease, including a history (before the normalization of laboratory parameters of liver function).
Hypersensitivity to the active substance or to any of the excipients.
Porphyria.
Recent Reviews